Vincent Keunen Joins NXgenPort Advisory Board

NXgenPort, a biomedical technology company developing products to provide doctors with remote patient monitoring, has appointed Vincent Keunen to its Board of Advisors.
 
“We are excited to have Vincent join our Board of Advisors. As a developing company, we know the value of having Vincent’s expertise in patient data and digital health platforms. All of us at NXgenPort look forward to working with Vincent in advancing our efforts in software product development,” said Dr. Rosanne Welcher, Chief Science Officer at NXgenPort.
 
When Keunen was diagnosed with leukemia in 2007, and his 10-year-old son was diagnosed with bone cancer three months later, he decided to use his software engineering skills to provide all patients with a tool to manage their health information on their smartphone. That platform can now be used to improve medical research by collecting RWE (real world evidence) and PRO (patient-reported outcomes) while facilitating telemedicine, remote patient monitoring, and continuity of care. 

“I’m pleased to join the Advisory Board at NXgenPort as I believe cancer patients need all the help they can get. I’ve been challenged by cancer myself as well as my 10-year-old son. The standard port-a-cath is already a significant improvement for the treatment, but a smart port would be so much more valuable.” said Keunen. “I am excited to work with the management team at NXgenPort and I’m convinced they are capable of great innovations.”

Keunen is the founder and CEO of Andaman7.  Previously, he developed numerous medical IT systems (a secure data exchange platform used by more than 90 percent of Belgian hospitals and family doctors, and a prevention EHR, managing today close to 1 million patients). 
 
The goal of NXgenPort’s medical device development efforts is to help healthcare providers like Mayo Clinic remotely monitor cancer patients at home with a smart implantable chemo-port catheter (patent pending). NXgenPort has a strategic collaboration with Mayo Clinic’s Foundation for Medical Education and Research. NXgenPort combines proven chemo-port efficacy with microchip and sensor technology to measure and remotely monitor early onset of complications by reporting and tracking patient response over the course of their treatment. 
 
According to NXgenPort Chief Science Officer Dr. Rosanne Welcher, “Support from Vincent will be invaluable in this stage of data collection, AI development, and software prototyping. We recognize the critical importance of having software expertise as well as the voice-of-the-patient built into our company development from the start. Having early input from Vincent will help us build a product that meets the needs of patients.” 
 
NXgenPort is designing a next-generation implantable chemo port-catheter utilizing microelectronic sensors that enable the remote management of patients by monitoring and reporting physiological body functions over the course of cancer treatment. NXgenPort is a startup company raising venture capital to enable product development and expansion of its intellectual property portfolio.